. 2023; 40(4): 242-250 | DOI: 10.4274/tjh.galenos.2023.2023.0029 | |||
Relaps/Refrakter Multipl Myelomda Daratumumab Deneyemi: Türkiye’den Çok Merkezli Bir ÇalışmaAtakan Tekinalp1, Ayfer Gedük2, Aydan Akdeniz3, Esra Terzi Demirsoy4, Vildan Gürsoy5, Müzeyyen Aslaner Ak6, Metin Bağcı7, Sema Seçilmiş8, Fatma Keklik Karadağ9, Ayşe Oruç Uysal10, Ali Doğan11, Sinan Demircioğlu1, Haşim Atakan Erol2, Ceyda Aslan4, Fahir Özkalemkaş12, Şehmus Ertop6, Mehmet Dağlı7, Mehmet Sinan Dal8, Güray Saydam9, Mustafa Merter10, Cihan Ural11, Özcan Çeneli11Necmettin Erbakan University Meram Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Konya, Türkiye2Kocaeli University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Kocaeli, Türkiye 3Mersin University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Mersin, Türkiye 4University of Health Sciences Türkiye, Derince Training and Research Hospital, Clinic of Hematology, Kocaeli, Türkiye 5Bursa City Hospital, Clinic of Hematology, Bursa, Türkiye 6Bülent Ecevit University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Zonguldak, Türkiye 7Selçuk University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Konya, Türkiye 8Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Clinic of Hematology, Ankara, Türkiye 9Ege University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, İzmir, Türkiye 10Fırat University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Elazığ, Türkiye 11Van Yüzüncü Yıl University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Van, Türkiye 12Bursa Uludağ University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Bursa, Türkiye Amaç: Bu çalışmanın amacı, relaps/refrakter multipl myelom (RRMM) tanısı ile daratumumab (DARA) kullanan hastaların değerlendirilmesidir. Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from TürkiyeAtakan Tekinalp1, Ayfer Gedük2, Aydan Akdeniz3, Esra Terzi Demirsoy4, Vildan Gürsoy5, Müzeyyen Aslaner Ak6, Metin Bağcı7, Sema Seçilmiş8, Fatma Keklik Karadağ9, Ayşe Oruç Uysal10, Ali Doğan11, Sinan Demircioğlu1, Haşim Atakan Erol2, Ceyda Aslan4, Fahir Özkalemkaş12, Şehmus Ertop6, Mehmet Dağlı7, Mehmet Sinan Dal8, Güray Saydam9, Mustafa Merter10, Cihan Ural11, Özcan Çeneli11Necmettin Erbakan University Meram Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Konya, Türkiye2Kocaeli University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Kocaeli, Türkiye 3Mersin University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Mersin, Türkiye 4University of Health Sciences Türkiye, Derince Training and Research Hospital, Clinic of Hematology, Kocaeli, Türkiye 5Bursa City Hospital, Clinic of Hematology, Bursa, Türkiye 6Bülent Ecevit University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Zonguldak, Türkiye 7Selçuk University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Konya, Türkiye 8Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Clinic of Hematology, Ankara, Türkiye 9Ege University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, İzmir, Türkiye 10Fırat University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Elazığ, Türkiye 11Van Yüzüncü Yıl University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Van, Türkiye 12Bursa Uludağ University Faculty of Medicine, Department of Hematology, Division of Internal Medicine, Bursa, Türkiye Objective: This study aimed to evaluate patients with relapsed/ refractory multiple myeloma (RRMM) who underwent daratumumab (DARA) therapy. Atakan Tekinalp, Ayfer Gedük, Aydan Akdeniz, Esra Terzi Demirsoy, Vildan Gürsoy, Müzeyyen Aslaner Ak, Metin Bağcı, Sema Seçilmiş, Fatma Keklik Karadağ, Ayşe Oruç Uysal, Ali Doğan, Sinan Demircioğlu, Haşim Atakan Erol, Ceyda Aslan, Fahir Özkalemkaş, Şehmus Ertop, Mehmet Dağlı, Mehmet Sinan Dal, Güray Saydam, Mustafa Merter, Cihan Ural, Özcan Çeneli. Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye. . 2023; 40(4): 242-250 Sorumlu Yazar: Atakan Tekinalp, Türkiye |
|